[1] JEMAL A, SIEGEL R, WARD E. Cancer statistics,2007, 2007(1)
[2] SYLVESTER RJ, van der MEIJDEN A P, OOSTERLINCK W. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables:a combined analysis of 2596 patients from seven EORTC trials. 2006(3). doi:10.1016/j.eururo.2005.12.031
[3] SYLVESTER RJ, OOSTERLINCK W, van der MEIJDEN A P. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer:a meta-analysis of published results of randomized clinical trials, 2004(6)
[4] CAMPODONICO F, MATTIOLI F, MANFREDI V. Pharmacokinetics and toxicity of an early single intravesical instillation of gemcitabine after endoscopic resection of superficial bladder cancer. 2007(2)
[5] MOSSBERG AK, WULLT B, GUSTAFSSON L. Bladder cancers respond to intravesical instillation of HAMLET (human alpha-lactalbumin made lethal to tumor cells). 2007(6). doi:10.1002/ijc.22810
[6] NATIV O, DALAL E, HIDAS G. EDTA-induced urothelial cell shedding for the treatment of superficial bladder cancer in the mouse. 2006(10). doi:10.1111/j.1442-2042.2006.01541.x
[7] SMITH EB, SCHWARTZ M, KAWAMOTO H. Antitumor effects of imidazoquinolines in urothelial cell carcinoma of the bladder. 2007(6). doi:10.1016/j.juro.2007.01.112
[8] HENDRICKSEN K, WITJES JA. Current strategies for first and second line intravesical therapy for nonmuscle invasive bladder cancer. 2007(5). doi:10.1097/MOU.0b013e3281c55f2b
[9] AU JL, BADALAMENT RA, WIENTJES MG. Methods to improve efficacy of intravesical mitomycin C:results of a randomized phase Ⅲ trial. 2001(8). doi:10.1093/jnci/93.8.597
[10] BARTOLETTI R, CAI T, GACCI M. Intravesical gemcitabine therapy for superficial transitional cell carcinoma:results of a phase Ⅱ prospective multicenter study. 2005(4). doi:10.1016/j.urology.2005.04.062
[11] DALBAGNI G, RUSSO P, BOCHNER B. Phase Ⅱ trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder. 2006(18). doi:10.1200/JCO.2005.05.2720
[12] van der HEIJDEN A G, MOONER P M, CORNEL E B. Phase Ⅱ marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer:toxicity and marker response. 2006(4). doi:10.1016/j.juro.2006.06.007
[13] MCKIERNAN JM, MASSON P, MURPHY AM. Phase Ⅰ trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy. 2006(19). doi:10.1200/JCO.2005.03.1161
[14] ROSATO A, BANZATO A, de LUCA G. HYTAD1-p20:a new paclitaxel-hyaluronic acid hydrosoluble bioconjugate for treatment of superficial bladder cancer. 2006(3). doi:10.1016/j.urolonc.2005.08.020
[15] MACKIE SJ, SHARMA DM, COOPER AJ. Meglumine Eicosapentaenoic acid (MeEPA) a new soluble omega-3 fatty acid formulation:in vitro bladder cancer cytotoxicity tests in combination with epirubicin and mitomycin. 2006(6). doi:10.1016/j.plefa.2006.07.002
[16] KAWANO H, KOMABA S, YAMASAKI T. New potential therapy for orthotopic bladder carcinoma by combining HVJ envelope with doxorubicin. 2008(6). doi:10.1007/s00280-007-0553-1
[17] GARDMARK T, JAHNSON S, WAHLQUIST R. Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and bacillus Calmette-Guérin in patients with high-risk bladder cancer. 2007(4). doi:10.1111/j.1464-410X.2006.06706.x
[18] FRIEDRICH MG, PICHLMEIER U, SCHWAIBOLD H. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma. 2007(4). doi:10.1016/j.eururo.2007.02.063
[19] van der MEIJDEN A P, SYLVESTER R J, OOSTERLINCK W. Maintenance bacillus calmette-guerin for Ta T1 bladder tumors is not associated with increased toxicity:results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase Ⅲ Trial. 2003(4). doi:10.1016/S0302-2838(3)00357-9
[20] COLOMBEL M, SAINT F, CHOPIN D. The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer:results of a randomized,prospective,double-blind,placebo controlled,multicenter study. 2006(3). doi:10.1016/j.juro.2006.04.104
[21] OJEA A, NOGUEIRA JL, SOLSONSA E. A multicentre,randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer:low-dose bacillus Calmette-Guerin (27mg) versus very low-dose bacillus Calmette-Guerin (13.5mg) versus mitomycin C. 2007(5). doi:10.1016/j.eururo.2007.04.062
[22] RAJALA P, KAASINEN E, RAITANEN M. Perioperative single dose instillation of epirubicin or interferon-alpha after transurethral resection for the prophylaxis of primary superficial bladder cancer recurrence:a prospective randomized multicenter study-FinnBladder Ⅲ long-term results, 2002(3)
[23] JOUDI FN, SMITH BJ, O'DONNELL MA. Final results from a national multicenter phase Ⅱ trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. 2006(4). doi:10.1016/j.urolonc.2005.11.026
[24] TAO Z, CONNOR RJ, ASHOORI F. Efficacy of a single intravesical treatment with Ad-IFN/Syn 3 is dependent on dose and urine IFN concentration obtained:implications for clinical investigation. 2006(2). doi:10.1038/sj.cgt.7700865
[25] NAGABHUSHAN TL, MANEVAL DC, BENEDICT WF. Enhancement of intravesical delivery with Syn3 potentiates interferon-alpha2b gene therapy for superficial bladder cancer. 2007(5-6). doi:10.1016/j.cytogfr.2007.06.007
[26] KASSOUF W, BLACK PC, TUZIAK T. Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer. 2008(1). doi:10.1016/j.juro.2007.08.087
[27] KASSOUF W, LUONGO T, BROWN G. Schedule dependent efficacy of gefitinib and docetaxel for bladder cancer. 2006(2)
[28] BLACK PC, AGARWAL PK, DINNEY CP. Targeted therapies in bladder cancer-an update. 2007(5). doi:10.1016/j.urolonc.2007.05.011
[29] WITJES JA, HENDRICKSEN K. Intravesical pharmacotherapy for non-muscle-invasive bladder cancer:a critical analysis of currently available drugs,treatment schedules,and long-term results. 2008(1). doi:10.1016/j.eururo.2007.08.015
[30] DISTASI SM, GIANNANYONI A, GIURIOLI A. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer:a randomised controlled trial. 2006(1). doi:10.1016/S1470-2045(5)70472-1
[31] STAVROPOULOS NE, KIM A, NSEYO UU. Hypericum perforatum L.extract-novel photosensitizer against human bladder cancer cells. 2006(1). doi:10.1016/j.jphotobiol.2006.02.001
[32] VAUCHER L, JICHLINSKI P, LANGE N. Hexyl-aminolevulinate-mediated photodynamic therapy:how to spare normal urothelium.An in vitro approach. 2007(1). doi:10.1002/lsm.20416 |
